Dose Insider / Glossary / Ileus

IleusWhen the bowel stops moving, and what GLP-1 labels say

Updated November 20, 2026 · 4 min read · MedlinePlus, FDA labels, cohort studies and meta-analyses

Ileus is a condition in which the bowel stops working correctly even though nothing is physically blocking it.

1.9UK cohort, GLP-1 medicine, obstruction per 1,000 a year
Obstruction per 1,000 a yearTwo cohorts, GLP-1 vs comparison drugUK COHORTGLP-1 medicine1.9Comparison drug1.1SCANDINAVIAN COHORTGLP-1 medicine1.3Comparison drug1.6Obstruction per 1,000 a yearTwo cohorts, GLP-1 vs comparison drugUK COHORTGLP-1 medicine1.9Comparison drug1.1SCANDINAVIAN COHORTGLP-1 medicine1.3Comparison drug1.6

The larger Scandinavian cohort found no increase.

On this page

MedlinePlus also calls it paralytic ileus or pseudo-obstruction, and sets it apart from mechanical obstruction, in which something partly or fully blocks the bowel.1 The labels of Ozempic, Wegovy, Zepbound and Mounjaro list ileus and intestinal obstruction among reactions reported after approval, without an estimate of how often they happen.2,3,4,5

What causes it

MedlinePlus lists the causes of ileus: abdominal surgery, chemical or mineral imbalances such as low blood potassium, infections inside the abdomen or the intestines, a reduced blood supply to the intestines, kidney or lung disease, and certain medicines, especially narcotics.1 Mechanical obstruction has its own list: scar tissue after surgery, hernias, tumors, impacted stool, a twisted intestine and inflammatory diseases such as Crohn disease, among others.1

Two of these causes link to the common side effects of GLP-1 medicines. Constipation is frequent, 24% on Wegovy and 11% to 17% on Zepbound in the label trials, and impacted stool is a mechanical cause of obstruction.1,3,4

What the labels say

Each of the four labels lists ileus, intestinal obstruction, and severe constipation including fecal impaction among stomach and gut reactions reported after approval. The labels explain that such reports come voluntarily from a population of uncertain size, so their frequency cannot be estimated reliably, nor can a cause be established. The clinical trials in the labels do not list obstruction or ileus among the reactions seen in the trials.2,3,4,5

What the studies found

None of these studies reports tirzepatide on its own.6,7,8,10 Taken together, the trials point away from a drug effect, while one large cohort found a modest rise. In either case the events were rare: about 1 to 2 per 1,000 people a year.

Timing and surgery

Common stomach side effects cluster around the dose steps, but obstruction may not. In the UK cohort the hazard ratio was highest after 1.6 years of use, at 3.48. The authors put the number needed to harm after one year at 1,223: one extra obstruction for every 1,223 people treated for a year.6 Surgery matters in two ways: abdominal surgery is a cause of ileus, with the bowel stopping for a time after an operation, and the adhesions it leaves come first on MedlinePlus's list of mechanical causes of obstruction.1

Warning signs

MedlinePlus lists the symptoms of intestinal obstruction: a swollen abdomen, fullness and gas, pain and cramping, bad breath, constipation or diarrhea, inability to pass gas, and nausea and vomiting.1 Its complications include dehydration, mineral imbalances, infection and a hole in the intestine, and a blockage that cuts off the blood supply can cause tissue death. Tests that show an obstruction include an abdominal CT scan and x-ray.1 Being unable to pass stool or gas, a swollen belly that does not go down, and vomiting that keeps on are reasons to seek care the same day. Our page on bowel obstruction on a GLP-1 covers risk factors, tests and treatment.

Sources

  1. MedlinePlus Medical Encyclopedia. Intestinal obstruction and ileus. U.S. National Library of Medicine; reviewed April 27, 2026, read November 20, 2026. medlineplus.gov
  2. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 5, 6.2 and 7. accessdata.fda.gov
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 5, 6.1, 6.2 and 7. accessdata.fda.gov
  4. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 5, 6.1, 6.2 and 7. accessdata.fda.gov
  5. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6.2 and 7. accessdata.fda.gov
  6. Faillie JL, Yin H, Yu OHY, et al. Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes. Clin Pharmacol Ther 2022;111:272-282. doi:10.1002/cpt.2430
  7. Ueda P, Wintzell V, Melbye M, et al. Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study. Clin Gastroenterol Hepatol 2024;22:1226-1237. doi:10.1016/j.cgh.2023.08.034
  8. Alfehaid L, Alyami M, Almohareb S, et al. Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis. Expert Opin Drug Saf 2026;25:1057-1065, published online February 2025. doi:10.1080/14740338.2025.2465870
  9. Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025;169:1268-1281. doi:10.1053/j.gastro.2025.06.003
  10. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 2023;330:1795-1797. doi:10.1001/jama.2023.19574

Related analyses

Log bowel movements and belly pain with your doses, so a change stands out early.

Open Dose Insider